Drug-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: A concise review

Therapeutic Apheresis and Dialysis

Volumn 8, Issue 2, 2004, Pages 102-111

  Dlott, Jeffrey S ^a   Danielson, Constance F M ^a,b   Blue Hnidy, Deborah E ^a   McCarthy, Leo J ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

Hemolytic uremic syndrome; Mitomycin; Thrombotic microangiopathy; Thrombotic thrombocytopenic purpura; Ticlopidine

Indexed keywords

ANTINEOPLASTIC AGENT; ANTITHROMBOCYTIC AGENT; BCG VACCINE; BLEOMYCIN; CIMETIDINE; CIPROFLOXACIN; CISPLATIN; CLARITHROMYCIN; CLOPIDOGREL; CYCLOPHOSPHAMIDE; DEXTRAN; DOXORUBICIN; EPIRUBICIN; FAMOTIDINE; FLUOROURACIL; GEMCITABINE; HEPARIN; IMMUNOMODULATING AGENT; INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE; METHOTREXATE; METRONIDAZOLE; MITOMYCIN; OXALIPLATIN; SIMVASTATIN; STEROID; TACROLIMUS; UNINDEXED DRUG; VINCA ALKALOID; VINCRISTINE;

BONE MARROW SUPPRESSION; CONFUSION; DIAGNOSTIC APPROACH ROUTE; DIALYSIS; DISORIENTATION; DRUG MECHANISM; HEMOLYTIC UREMIC SYNDROME; HUMAN; KIDNEY FAILURE; LUNG FIBROSIS; NEUROTOXICITY; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; SEIZURE; SPLENECTOMY; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ANTINEOPLASTIC AGENTS; HEMOLYTIC-UREMIC SYNDROME; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PLATELET AGGREGATION INHIBITORS; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

EID: 2942750005     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1526-0968.2003.00127.x     Document Type: Review

References (131)

1. Medina PJ, Sipols JM, George JN. Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol 2001;8:286-93.
2. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996;87:4235-44.
3. Furlan M, Robles R, Galbusera M et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998;339:1578-84.
4. Furlan M, Lammle B. Haemolytic-uraemic syndrome and thrombotic thrombocytopenic purpura - new insights into underlying biochemical mechanisms. Nephrol Dial Transplant 2000;15:1112-14.
5. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998;339:1585-94.
6. Mori Y, Wada H, Gabazza EC et al. Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity. Transfusion 2002;42:572-80.
7. Hunt BJ, Lammle B, Nevard CH, Haycock GB, Furlan M. von Willebrand factor-cleaving protease in childhood diarrhoea-associated haemolytic uraemic syndrome. Thromb Haemost 2001;85:975-8.
8. Veyradier A, Obert B, Houllier A, Meyer D, Girma JP. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 2001;98:1765-72.
9. Remuzzi GM, Norris M, Canciani MT et al. von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Blood 2002;100:778-85.
10. Vesely SK, George JN, Lammle B et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003;102:60-8.
11. Tsai HM, Rice L, Sarode R, Chow TW, Moake JL. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann Intern Med 2000;132:794-9.
12. Lattuada A, Rossi E, Calzarossa C, Candolfi R, Mannucci PM. Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome. Haematologica 2003;88:1029-34.
13. Mannucci PM, Vanoli M, Forza I, Canciani MT, Scorza R. Von Willebrand factor cleaving protease (ADAMTS-13) in 123 patients with connective tissue diseases (systemic lupus erythematosus and systemic sclerosis). Haematologica 2003;88:914-18.
14. Veyradier AOB, Haddad E, Cloarec S, Nivet H, Foulard M. Severe deficiency of the specific von Willebrand factor-cleaving protease (ADAMTS13) activity in a subgroup of children with atypical hemolytic uremic syndrome. J Pediatr 2003;142:310-17.
15. Liu K, Mittelman A, Sproul EE, Elias EG. Renal toxicity in man treated with mitomycin C. Cancer 1971;28:1314-20.
16. Krauss S, Sonoda T, Solomon A. Treatment of advanced gastrointestinal cancer with 5-fluorouracil and mitomycin C. Cancer 1979;43:1598-603.
17. Hanna WT, Krauss S, Regester RF, Murphy WM. Renal disease after mitomycin C therapy. Cancer 1981;48:2583-8.
18. Cantrell JE Jr, Phillips TM, Schein PS. Carcinoma-associated hemolytic-uremic syndrome, a complication of mitomycin C chemotherapy. J Clin Oncol 1985;3:723-34.
19. Valavaara R, Nordman E. Renal complications of mitomycin C therapy with special reference to the total dose. Cancer 1985;55:47-50.
20. Sheldon R, Slaughter D. A syndrome of microangiopathic hemolytic anemia, renal impairment, and pulmonary edema in chemotherapy-treated patients with adenocarcinoma. Cancer 1986;58:1428-36.
21. Lesesne JB, Rothschild N, Erickson B et al. Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol 1989;7:781-9.
22. Snyder HW Jr, Mittelman A, Oral A et al. Treatment of cancer chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome by protein A immunoadsorption of plasma. Cancer 1993;71:1882-92.
23. Nishiyama Y, Komaba Y, Kitamura H, Katayama Y. Hemolytic uremic syndrome with intracranial hemorrhage following mitomycin C administration. Intern Med 2001;40:237-40.
24. Brain MC. Microangiopathic haemolytic anaemia (MHA). Br J Haematol 1972;23:45-52.
25. Murgo AJ. Thrombotic microangiopathy in the cancer patient including those induced by chemotherapeutic agents. Semin Hematol 1987;24:161-77.
26. Cattell V. Mitomycin-induced hemolytic uremic kidney. An experimental model in the rat. Am J Pathol 1985;121:88-95.
27. Montes A, Powles TJ, O'Brien ME, Ashley SE, Luckit J, Treleaven J. A toxic interaction between mitomycin C and tamoxifen causing the haemolytic uraemic syndrome. Eur J Cancer 1993;29A:1854-7.
28. Zimmerman SE, Smith FP, Phillips TM, Coffey RJ, Schein PS. Gastric carcinoma and thrombotic thrombocytopenic purpura: association with plasma immune complex concentrations. Br Med J 1982;284:1432-4.
29. Gulati SC, Sordillo P, Kempin S et al. Microangiopathic anemia observed after treatment of epidermoid carcinoma with mitomycin C and 5-fluorouracil. Cancer 1980;45:2252-7.
30. Lempert KD. Haemolysis and renal impairment syndrome in patients on 5-fluorouracil and mitomycin-C. Lancet 1980;2:369-70.
31. Korec S, Schein PS, Smith FP et al. Treatment of cancer-associated hemolytic uremic syndrome with staphylococcal protein A immunoperfusion. J Clin Oncol 1986;4:210-15.
32. Jackson AM, Rose BD, Graff LG et al. Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy. Ann Intern Med 1984;101:41-4.
33. Gardner G, Mesler D, Gitelman HJ. Hemolytic uremic syndrome following cisplatin, bleomycin, and vincristine chemotherapy. A report of a case and a review of the literature. Ren Fail 1989;11:133-7.
34. Angiola G, Bloss JD, DiSaia PJ, Warner AS, Manetta A, Berman ML. Hemolytic-uremic syndrome associated with neoadjuvant chemotherapy in the treatment of advanced cervical cancer. Gynecol Oncol 1990;39:214-17.
35. Gradishar WJ, Vokes EE, Ni K, Panje WR. Chemotherapy-related hemolytic-uremic syndrome after the treatment of head and neck cancer. A case report. Cancer 1990;66:1914-18.
36. Porta C, Danova M, Riccardi A, Bobbio-Pallavicini E, Ascari E. Cancer chemotherapy-related thrombotic thrombocytopenic purpura: biological evidence of increased nitric oxide production. Mayo Clin Proc 1999;74:570-4.
37. Thurnher D, Kletzmayr J, Formanek M et al. Chemotherapy-related hemolytic-uremic syndrome following treatment of a carcinoma of the nasopharynx. Oncology 2001;61:143-6.
38. Licciardello JT, Moake JL, Rudy CK, Karp DD, Hong WK. Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy. Oncology 1985;42:296-300.
39. Canoplat CPP, Jaffe N. Cisplatin-associated hemolytic uremic syndrome. Cancer 1994;74:3059-62.
40. Palmisano J, Agraharkar M, Kaplan AA. Successful treatment of cisplatin-induced hemolytic uremic syndrome with therapeutic plasma exchange. Am J Kidney Dis 1998;32:314-17.
41. Rabinowits G, Herchenhorn D, Rabinowits M, Weatge D, Torres W. Fatal pulmonary toxicity in a patient treated with gefitinib for non-small cell lung cancer after previous hemolytic-uremic syndrome due to gemcitabine. Anticancer Drugs 2003;14:665-8.
42. Alberts SR, Townley PM, Goldberg RM et al. Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II study. Ann Oncol 2003;14:580-5.
43. Citarrella P, Gebbia V, Teresi M et al. Hemolytic uremic syndrome after chemotherapy with gemcitabine and taxotere: a case report. Anticancer Res 2002;22:1183-5.
44. Fung MC, Storniolo AM, Nguyen B, Arning M, Brookfield W, Vigil J. A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer 1999;85:2023-32.
45. Byrnes JJ, Baquerizo H, Gonzalez M, Hensely GT. Thrombotic thrombocytopenic purpura subsequent to acute myelogenous leukemia chemotherapy. Am J Hematol 1986;21: 299-304.
46. Harris DC, Lawrence S, Bradstock KF, Carter JJ, Jones WG. Intraglomerular thrombosis with deoxycoformycin - reversible acute renal failure. Clin Nephrol 1984;21:194-6.
47. Sakai C, Takagi T, Wakatsuki S, Matsuzaki O. Hemolytic-uremic syndrome due to deoxycoformycin: a report of the second case. Intern Med 1995;34:593-6.
48. Leach JW, Pham T, Diamandidis D, George JN. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) following treatment with deoxycoformycin in a patient with cutaneous T-cell lymphoma (Sezary syndrome): a case report. Am J Hematol 1999;61:268-70.
49. Agarwal A, Mauer SM, Matas AJ, Nath KA. Recurrent hemolytic uremic syndrome in an adult renal allograft recipient. Current concepts and management. J Am Soc Nephrol 1995;6:1160-9.
50. Remuzzi GBT. Renal vascular and thrombotic effects of cyclosporine. Am J Kidney Dis 1989;13:261-72.
51. Pettitt AR, Clark RE. Thrombotic microangiopathy following bone marrow transplantation. Bone Marrow Transplant 1994;14:495-504.
52. Zarifian A, Meleg-Smith S, O'Donovan R, Tesi RJ, Batuman V. Cyclosporine-associated thrombotic microangiopathy in renal allografts. Kidney Int 1999;55:2457-66.
53. Mihatsch MJ, Kyo M, Morozumi K, Yamaguchi Y, Nickeleit V, Ryffel B. The side-effects of ciclosporine-A and tacrolimus. Clin Nephrol 1998;49:356-63.
54. Young BA, Marsh CL, Alpers CE, Davis CL. Cyclosporine-associated thrombotic microangiopathy/hemolytic uremic syndrome following kidney and kidney-pancreas transplantation. Am J Kidney Dis 1996;28:561-71.
55. Katznelson S, Wilkinson A, Rosenthal TR, Cohen A, Nast C, Danovitch GM. Cyclosporine-induced hemolytic uremic syndrome: factors that obscure its diagnosis. Transplant Proc 1994;26:2608-9.
56. Van Buren D, Van Buren CT, Flechner SM, Maddox AM, Verani R, Kahan BD. De novo hemolytic uremic syndrome in renal transplant recipients immunosuppressed with cyclosporine. Surgery 1985;98:54-62.
57. Zent R, Katz A, Quaggin S et al. Thrombotic microangiopathy in renal transplant recipients treated with cyclosporin A. Clin Nephrol 1997;47:181-6.
58. Hauben M. Cyclosporine neurotoxicity. Pharmacotherapy 1996;16:576-83.
59. Schriber JR, Herzig GP. Transplantation-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Semin Hematol 1997;34:126-33.
60. Bunchman TE, Brookshire CA. Cyclosporine-induced synthesis of endothelin by cultured human endothelial cells. J Clin Invest 1991;88:310-14.
61. Dzik WH, Georgi BA, Khettry U, Jenkins RL. Cyclosporine-associated thrombotic thrombocytopenic purpura following liver transplantation - successful treatment with plasma exchange. Transplantation 1987;44:570-2.
62. Lapointe M, Baillie GM, Bhaskar SS et al. Cyclosporine-induced hemolytic uremic syndrome and hemorrhagic colitis following renal transplantation. Clin Transplant 1999;13:526-30.
63. Myers JN, Shabshab SF, Burton NA, Nathan SD. Successful use of cyclosporine in a lung transplant recipient with tacrolimus-associated hemolytic uremic syndrome. J Heart Lung Transplant 1999;18:1024-6.
64. Chinnakotla S, Leone JP, Fidler ME, Hammeke MD, Tarantolo S. Clopidogrel-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in a kidney/pancreas transplant recipient. Transplantation 2000;70:550-2.
65. Randhawa PS, Tsamandas AC, Magnone M et al. Microvascular changes in renal allografts associated with FK506 (Tacrolimus) therapy. Am J Surg Pathol 1996;20:306-12.
66. Trimarchi HM, Truong LD, Brennan S, Gonzalez JM, Suki WN. FK506-associated thrombotic microangiopathy: report of two cases and review of the literature. Transplantation 1999;67:539-44.
67. Abdalla AH, al-Sulaiman MH, al-Khader AA. FK 506 as an alternative in cyclosporin-induced hemolytic uremic syndrome in a kidney transplant recipient. Transpl Int 1994;7:382-4.
68. Kaufman DB, Kaplan B, Kanwar YS, Abecassis M, Stuart FP. The successful use of tacrolimus (FK506) in a pancreas/kidney transplant recipient with recurrent cyclosporine-associated hemolytic uremic syndrome. Transplantation 1995;59:1737-9.
69. Trimarchi H, Freixas E, Rabinovich O, Schropp J, Pereyra H, Bullorsky E. Cyclosporine-associated thrombotic microangiopathy during daclizumab induction: a suggested therapeutic approach. Nephron 2001;87:361-4.
70. Abramowicz D, Pradier O, Marchant A et al. Induction of thromboses within renal grafts by high-dose prophylactic OKT3. Lancet 1992;339:777-8.
71. Burke GW, Ciancio G, Cirocco R et al. Microangiopathy in kidney and simultaneous pancreas/kidney recipients treated with tacrolimus: evidence of endothelin and cytokine involvement. Transplantation 1999;68:1336-42.
72. Harvey M, Rosenfeld D, Davies D, Hall BM. Recombinant interferon alpha and hemolytic uremic syndrome: cause or coincidence? Am J Hematol 1994;46:152-3.
73. Honda K, Ando A, Endo M et al. Thrombotic microangiopathy associated with alpha-interferon therapy for chronic myelocytic leukemia. Am J Kidney Dis 1997;30:123-30.
74. Iyoda K, Kato M, Nakagawa T et al. Thrombotic thrombocytopenic purpura developed suddenly during interferon treatment for chronic hepatitis C. J Gastroenterol 1998;33:588-92.
75. Lacotte L, Thierry A, Delwail V, Dreyfus B, Guilhot F. Thrombotic thrombocytopenic purpura during interferon alpha treatment for chronic myelogenous leukemia. Acta Haematol 2000;102:160-2.
76. Magee CC. Renal thrombotic microangiopathy induced by interferon-alpha. Nephrol Dial Transplant 2001;16: 2111-12.
77. Rachmani R, Avigdor A, Youkla M et al. Thrombotic thrombocytopenic purpura complicating chronic myelogenous leukemia treated with interferon-alpha. A report of two successfully treated patients. Acta Haematol 1998;100:204-6.
78. Ravandi-Kashani F, Cortes J, Talpaz M, Kantarjian HM. Thrombotic microangiopathy associated with interferon therapy for patients with chronic myelogenous leukemia: coincidence or true side effect? Cancer 1999;85:2583-8.
79. Schlaifer D, Dumazer P, Spenatto N et al. Hemolytic-uremic syndrome in a patient with chronic myelogenous leukemia treated with interferon alpha. Am J Hematol 1994;47:254-5.
80. Stratta P, Canavese C, Dogliani M et al. Hemolytic-uremic syndrome during recombinant alpha-interferon treatment for hairy cell leukemia. Ren Fail 1993;15:559-61.
81. Vacher-Coponat H, Opris A, Daniel L, Harle JR, Veit V, Olmer M. Thrombotic microangiopathy in a patient with chronic myelocytic leukaemia treated with alpha-interferon. Nephrol Dial Transplant 1999;14:2469-71.
82. Al-Zahrani H, Gupta V, Minden MD, Messner HA, Lipton JH. Vascular events associated with alpha interferon therapy. Leuk Lymphoma 2003;44:471-5.
83. Piette JC, Papo T. Potential role for antiphospholipid antibodies in renal thrombotic microangiopathy induced by interferon-alpha. Nephrol Dial Transplant 1995;10:1781.
84. Ronnblom LE, Alm GV, Oberg KE. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 1991;115:178-83.
85. Ault BH, Stapleton FB, Gaber L, Martin A, Roy S 3rd, Murphy SB. Acute renal failure during therapy with recombinant human gamma interferon. N Engl J Med 1988;319:1397-400.
86. Averbuch SD, Austin HA 3rd, Sherwin SA, Antonovych T, Bunn PA Jr, Longo DL. Acute interstitial nephritis with the nephrotic syndrome following recombinant leukocyte a interferon therapy for mycosis fungoides. N Engl J Med 1984;310:32-5.
87. Gottschall JL, Elliot W, Lianos E, McFarland JG, Wolfmeyer K, Aster RH. Quinine-induced immune thrombocytopenia associated with hemolytic uremic syndrome: a new clinical entity. Blood 1991;77:306-10.
88. Kojouri K, Vesely SK, George JN. Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, frequency, clinical features, and long-term outcomes. Ann Intern Med 2001;135:1047-51.
89. Stroncek DF, Vercellotti GM, Hammerschmidt DE, Christie DJ, Shankar RA, Jacob HS. Characterization of multiple quinine-dependent antibodies in a patient with episodic hemolytic uremic syndrome and immune agranulocytosis. Blood 1992;80:241-8.
90. Kedia RK, Wright AJ. Quinine-mediated disseminated intravascular coagulation. Postgrad Med J 1999;75:429-30.
91. Farver DK, Lavin MN. Quinine-induced hepatotoxicity. Ann Pharmacother 1999;33:32-4.
92. Glynne P, Salama A, Chaudhry A, Swirsky D, Lightstone L. Quinine-induced immune thrombocytopenic purpura followed by hemolytic uremic syndrome. Am J Kidney Dis 1999;33:133-7.
93. Gottschall JL, Neahring B, McFarland JG, Wu GG, Weitekamp LA, Aster RH. Quinine-induced immune thrombocytopenia with hemolytic uremic syndrome, clinical and serological findings in nine patients and review of literature. Am J Hematol 1994;47:283-9.
94. Crum NF, Gable P. Quinine-induced hemolytic-uremic syndrome. South Med J 2000;93:726-8.
95. Sharis PJ, Cannon CP, Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med 1998;129:394-405.
96. Bennett CL, Connors JM, Carwile JM et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000;342:1773-7.
97. Perotti C, Torretta L, Costamagna L, Salvaneschi L. Thrombotic thrombocytopenic purpura after defibrotide therapy. Haematologica 1994;79:569.
98. Page Y, Tardy B, Zeni F, Comtet C, Terrana R, Bertrand JC. Thrombotic thrombocytopenic purpura related to ticlopidine. Lancet 1991;337:774-6.
99. Steinhubl SR, Tan WA, Foody JM, Topol EJ. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of platelet IIb/IIIa inhibitor for stenting. JAMA 1999;281:806-10.
100. Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, Yarnold PR, Kwaan HC, Green D. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann Intern Med 1998;128:541-4.
101. Bennett CL, Davidson CJ, Raisch DW, Weinberg PD, Bennett RH, Feldman MD. Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention. Arch Intern Med 1999;159:2524-8.
102. Bennett CL, Kiss JE, Weinberg PD et al. Thrombotic thrombocytopenic purpura after stenting and ticlopidine. Lancet 1998;352:1036-7.
103. Vianelli N, Catani L, Belmonte MM et al. Ticlopidine in the treatment of thrombotic thrombocytopenic purpura: report of two cases. Haematologica 1990;75:274-7.
104. Moy B, Wang JC, Raffel GD, Marcoux JP 2nd, Hemolytic uremic syndrome associated with clopidogrel: a case report. Arch Intern Med 2000;160:1370-2.
105. Oomen PH, Tulleken JE, Zijlstra JG, Hemolytic uremic syndrome in a patient treated with clopidogrel. Ann Intern Med 2000;132:1006.
106. Paradiso-Hardy FL, Papastergiou J, Lanctot KL, Cohen EA. Thrombotic thrombocytopenic purpura associated with clopidogrel: further evaluation. Can J Cardiol 2002;18:771-3.
107. Allan DS, Thompson CM, Barr RM, Clark WF, Chin-Yee IH. Ciprofloxacin-associated hemolytic-uremic syndrome. Ann Pharmacother 2002;36:1000-2.
108. Alexopoulou A, Dourakis SP, Kaloterakis A, Thrombotic thrombocytopenic purpura in a patient treated with clarithromycin. Eur J Haematol 2002;69:191-2.
109. Baron BW, van Besien K, Hoffman PC, Kohn OF, Rossof AH, Baron JM. Thrombotic thrombocytopenic purpura after cephalosporin administration: a possible relationship. Transfusion 2003;43:1317-21.
110. Yata Y, Miyagiwa M, Inatsuchi S et al. Thrombotic thrombocytopenia purpura caused by piperacillin successfully treated with plasma infusion. Ann Hematol 2000;79:593-5.
111. Powell HR, Davidson PM, McCredie DA, Phair P, Walker RG. Haemolytic-uraemic syndrome after treatment with metronidazole. Med J Aust 1988;149:222-3.
112. Parker JC, Barrett DA 2nd. Microangiopathic hemolysis and thrombocytopenia related to penicillin drugs. Arch Intern Med 1971;127:474-7.
113. Trice JM, Pinals RS, Plitman GI. Thrombotic thrombocytopenic purpura during penicillamine therapy in rheumatoid arthritis. Arch Intern Med 1983;143:1487-8.
114. Ahmed F, Sumalnop V, Spain DM, Tobin MS. Thrombohemolytic thrombocytopenic purpura during penicillamine therapy. Arch Intern Med 1978;138:1292-3.
115. Speth PA, Boerbooms AM, Holdrinet RS, Van de Putte LB, Meyer JW. Thrombotic thrombocytopenic purpura associated with d-penicillamine treatment in rheumatoid arthritis. J Rheumatol 1982;9:812-13.
116. Fahal IH, Williams PS, Clark RE, Bell GM. Thrombotic thrombocytopenic purpura due to rifampicin. BMJ 1992; 304:882.
117. Kallal SM, Lee M. Thrombotic thrombo-cytopenic purpura associated with histamine H2-receptor antagonist therapy. West J Med 1996;164:446-8.
118. Hauglustaine D, Van Damme B, Vanrenterghem Y, Michielsen P. Recurrent hemolytic uremic syndrome during oral contraception. Clin Nephrol 1981;15:148-53.
119. McShane PM, Bern MM, Schiff I. Thrombotic thrombocytopenic purpura associated with oral contraceptives: a case report. Am J Obstet Gynecol 1983;145:762-3.
120. Liang R, Wong RW, Cheng IK. Thrombotic thrombocytopenic purpura and 17 beta-estradiol transdermal skin patch. Am J Hematol 1996;52:334-5.
121. Au WY, Chan KW, Lam CC, Young K. A post-menopausal woman with anuria and uterus bulk: the spectrum of estrogen-induced TTP/HUS. Am J Hematol 2002;71:59-60.
122. Keung YK, Morgan D, Cobos E. Cocaine-induced microangiopathic hemolytic anemia and thrombocytopenia simulating thrombotic thrombocytopenia purpura. Ann Hematol 1996;72:155-6.
123. Volcy J, Nzerue CM, Oderinde A, Hewan-Iowe K. Cocaine-induced acute renal failure, hemolysis, and thrombocytopenia mimicking thrombotic thrombocytopenic purpura. Am J Kidney Dis 2000;35:E3.
124. Tumlin JA, Sands JM, Someren A. Hemolytic-uremic syndrome following 'crack' cocaine inhalation. Am J Med Sci 1990;299:366-71.
125. Schirren CA, Berghaus TM, Sackmann M. Thrombotic thrombocytopenic purpura after Ecstasy-induced acute liver failure. Ann Intern Med 1999;130:163.
126. Peces R, Diaz-Corte C, Baltar J, Seco M, Alvarez-Grande J. Haemolytic-uraemic syndrome in a heroin addict. Nephrol Dial Transplant 1998;13:3197-9.
127. McCarthy LJ, Porcu P, Fausel CA, Sweeney CJ, Danielson CF. Thrombotic thrombocytopenic purpura and simvastatin. Lancet 1998;352:1284-5.
128. McCarthy LJ et al. TTP induced by Lipitor [Abstract]. Vox Sang 2000;78:PO41.
129. Brown RC, Blecher TE, French EA, Toghill PJ. Thrombotic thrombocytopenic purpura after influenza vaccination. Br Med J 1973;2:303.
130. Karim Y, Masood A. Haemolytic uraemic syndrome following mumps, measles, and rubella vaccination. Nephrol Dial Transplant 2002;17:941-2.
131. Peyriere H, Klouche K, Beraud JJ, Blayac JP, Hillaire-Buys D. Fatal systemic reaction after multiple doses of intravesical bacillus Calmette-Guerin for polyposis. Ann Pharmacother 2000;34:1279-82.